NCT01172691

Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts

Randomized, Blinded, Controlled Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Baylor Research Institute · Academic / Other
• Sex: All
• Age: 17 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to determine if patients receiving (iNO) will have increased liver function and less damage from IR than patients who do not receive (iNO).

Conditions

• Liver Transplant

Interventions

Type	Name	Description
DRUG	Inhaled Nitric Oxide (iNO)	iNO will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
DRUG	Placebo Arm (Nitrogen)	Placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU

Timeline

• Start date: 2010-07-01
• Primary completion: 2014-01-22
• Completion: 2014-01-22
• First posted: 2010-07-30
• Last updated: 2026-01-28

Locations

1 site across 1 country: United States